SW-682 in Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumor, Mesothelioma, Malignant

In brief

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.

Key facts

Study ID
NCT06251310
Run by
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
People needed
186
Starts
2024-07-31
Expected to finish
2027-01-18
Last updated by the study team
2026-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.